Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Current opinion in pharmacology (Print)

• Publication date

  2015-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.coph.2015.05.014PMID 26079328
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers.

  2015cited by this paper
• ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells

  2015cited by this paper
• Combination of ibrutinib with ABT‐199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways

  2015cited by this paper
• Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

  2015cited by this paper
• B Cell Lymphoma-2 (BCL-2) Homology Domain 3 (BH3) Mimetics Demonstrate Differential Activities Dependent upon the Functional Repertoire of Pro- and Anti-apoptotic BCL-2 Family Proteins*

  2014cited by this paper
• Obatoclax Mesylate, a Pan–Bcl-2 Inhibitor, in Combination with Docetaxel in a Phase 1/2 Trial in Relapsed Non–Small-Cell Lung Cancer

  2014cited by this paper
• Apogossypolone, a small-molecule inhibitor of Bcl-2, induces radiosensitization of nasopharyngeal carcinoma cells by stimulating autophagy.

  2014cited by this paper
• Pan-Bcl-2 Inhibitor Obatoclax Delays Cell Cycle Progression and Blocks Migration of Colorectal Cancer Cells

  2014cited by this paper
• ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.

  2014cited by this paper
• A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma

  2014cited by this paper
• Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.

  2014cited by this paper
• ABT-199 shows effectiveness in CLL.

  2014cited by this paper
• Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.

  2014cited by this paper
• Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101.

  2014cited by this paper
• Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

  2014cited by this paper
• A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

  2014cited by this paper
• Gossypol Increases Expression of the Pro-apoptotic BH3-only Protein NOXA through a Novel Mechanism Involving Phospholipase A2, Cytoplasmic Calcium, and Endoplasmic Reticulum Stress*

  2014cited by this paper
• A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia.

  2014cited by this paper
• Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts

  2014cited by this paper
• Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2/Mcl-1 pathway

  2014cited by this paper
• A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia

  2014cited by this paper
• RhoA/ROCK/PTEN signaling is involved in AT-101-mediated apoptosis in human leukemia cells in vitro and in vivo

  2014cited by this paper
• The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors

  2014cited by this paper
• Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

  2014cited by this paper
• ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells

  2013cited by this paper
• The novel BH-3 mimetic apogossypolone induces Beclin-1- and ROS-mediated autophagy in human hepatocellular carcinoma cells

  2013cited by this paper
• The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA

  2013cited by this paper
• That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance

  2013cited by this paper
• Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes

  2013cited by this paper
• The novel BH-3 mimetic apogossypolone induces Beclin-1- and ROS-mediated autophagy in human hepatocellular cells

  2013cited by this paper
• Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.

  2013cited by this paper
• Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer.

  2013cited by this paper
• Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.

  2013cited by this paper
• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

  2013cited by this paper
• OBATOCLAX and ABT-737 Induce ER Stress Responses in Human Melanoma Cells that Limit Induction of Apoptosis

  2013cited by this paper
• ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.

  2013cited by this paper
• Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.

  2012cited by this paper
• A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer

  2012cited by this paper
• Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

  2012cited by this paper
• Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

  2012cited by this paper
• Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin vs. obatoclax.

  2012cited by this paper
• Direct and selective small-molecule activation of proapoptotic BAX.

  2012cited by this paper
• Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models

  2012cited by this paper
• Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.

  2012cited by this paper
• A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival.

  2012cited by this paper
• The BH3 mimetic S1 induces autophagy through ER stress and disruption of Bcl-2/Beclin 1 interaction in human glioma U251 cells.

  2012cited by this paper
• The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

  2011cited by this paper
• BH3 mimetics activate multiple pro-autophagic pathways

  2011cited by this paper
• Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer

  2011cited by this paper
• A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• A novel BH3 mimetic S1 potently induces Bax/Bak‐dependent apoptosis by targeting both Bcl‐2 and Mcl‐1

  2011cited by this paper
• A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.

  2011cited by this paper
• A unified model of mammalian BCL-2 protein family interactions at the mitochondria.

  2011cited by this paper
• Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

  2011cited by this paper
• The Pan-Bcl-2 Inhibitor (−)-Gossypol Triggers Autophagic Cell Death in Malignant Glioma

  2010cited by this paper
• Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

  2010cited by this paper
• GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy

  2010cited by this paper
• A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells.

  2010cited by this paper
• Different forms of cell death induced by putative BCL2 inhibitors

  2009cited by this paper
• ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway

  2009cited by this paper
• BCL-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress

  2009cited by this paper
• Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737

  2009cited by this paper
• Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo

  2008cited by this paper
• ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

  2008cited by this paper
• A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells

  2008cited by this paper
• BH3-only proteins in apoptosis and beyond: an overview

  2008cited by this paper
• Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

  2008cited by this paper
• Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells.

  2008cited by this paper
• BCL-2 family antagonists for cancer therapy

  2008cited by this paper
• Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins

  2008cited by this paper
• ApoG2 inhibits antiapoptotic Bcl-2 family proteins and induces mitochondria-dependent apoptosis in human lymphoma U937 cells

  2008cited by this paper
• Inducing apoptosis and enhancing chemosensitivity to Gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell

  2008cited by this paper
• BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.

  2008cited by this paper
• Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).

  2008cited by this paper
• Regulation of antiapoptotic MCL-1 function by gossypol: mechanistic insights from in vitro reconstituted systems.

  2008cited by this paper
• ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells

  2007cited by this paper
• Bcl-2 family proteins are essential for platelet survival

  2007cited by this paper
• The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.

  2007cited by this paper
• Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048).

  2006cited by this paper
• Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.

  2006cited by this paper
• Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

  2006cited by this paper
• An inhibitor of Bcl-2 family proteins induces regression of solid tumours

  2005cited by this paper
• Rational Design and Real Time, In-Cell Detection of the Proapoptotic Activity of a Novel Compound Targeting Bcl-XL

  2004cited by this paper
• Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L).

  2004cited by this paper
• Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins.

  2003cited by this paper
• Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial

  2001cited by this paper
• Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis

  1997cited by this paper
• Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

  1988cited by this paper
• Involvement of the bcl-2 gene in human follicular lymphoma.

  1985cited by this paper
• A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia.

  1984cited by this paper

• Gossypol in the nanomedicine era: Overcoming clinical bottlenecks and unlocking antitumor potential

  2026cites this paper
• The Role of the BCL2 Family in Targeted Anticancer Response as Apoptotic Mediators

  2025cites this paper
• First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies

  2025cites this paper
• Research progress on the bioactivity of platycodin D from Platycodon grandifloras

  2025cites this paper
• Heparanase inhibitor OGT 2115 induces prostate cancer cell apoptosis via the downregulation of MCL‑1

  2024cites this paper
• Emerging biomarkers and potential therapeutics of the BCL-2 protein family: the apoptotic and anti-apoptotic context

  2024cites this paper
• Site-Specifically Modified Peptide Inhibitors of Protein Tyrosine Phosphatase 1B and T-Cell Protein Tyrosine Phosphatase with Enhanced Stability and Improved In Vivo Long-Acting Activity.

  2024cites this paper
• In Silico Mining of Natural Products Atlas (NPAtlas) Database for Identifying Effective Bcl-2 Inhibitors: Molecular Docking, Molecular Dynamics, and Pharmacokinetics Characteristics

  2023cites this paper
• Regorafenib induces Bim-mediated intrinsic apoptosis by blocking AKT-mediated FOXO3a nuclear export

  2023cites this paper
• Dinaciclib synergizes with BH3 mimetics targeting BCL‐2 and BCL‐XL in multiple myeloma cell lines partially dependent on MCL‐1 and in plasma cells from patients

  2023cites this paper
• Molecular docking studies of Brucein D as a potential inhibitor of the Bcl-2 anti-apoptotic protein

  2023cites this paper
• Discovery of Novel PTP1B Inhibitors with Once-Weekly Therapeutic Potential for Type 2 Diabetes: Design, Synthesis, and In Vitro and In Vivo Investigations of BimBH3 Peptide Analogues.

  2023cites this paper
• Anticancer effects of putative and validated BH3-mimetic drugs in head and neck squamous cell carcinomas: An overview of current knowledge.

  2022cites this paper
• Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces

  2022cites this paper
• Hypericin, a potential new BH3 mimetic

  2022cites this paper
• Dichotomous role of autophagy in cancer

  2022cites this paper
• Comparison of the efficacy of gossypol acetate enantiomers in rats with uterine leiomyoma

  2022cites this paper
• Investigation of nickel sulfate‐induced cytotoxicity and underlying toxicological mechanisms in human umbilical vein endothelial cells through oxidative stress, inflammation, apoptosis, and MAPK signaling pathways

  2022cites this paper
• Cell-penetrating Alphabody protein scaffolds for intracellular drug targeting

  2021cites this paper
• Identification of novel Src, Bcl-2 dual inhibitors by the pharmacophore model, molecular docking, and molecular dynamics simulations

  2021cites this paper
• Discovery of Novel PTP1B Inhibitors Derived from the BH3 Domain of Proapoptotic Bcl-2 Proteins with Antidiabetic Potency.

  2021cites this paper
• Gastrointestinal response to biomaterials

  2020cites this paper
• Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer

  2020cites this paper
• Selective Affimers Recognise the BCL‐2 Family Proteins BCL‐xL and MCL‐1 through Noncanonical Structural Motifs**

  2020cites this paper
• ABT-263 exhibits apoptosis-inducing potential in oral cancer cells by targeting C/EBP-homologous protein

  2019cites this paper
• Heteroleptic copper(i) halides with triphenylphosphine and acetylthiourea: synthesis, characterization and biological studies (experimental and molecular docking)

  2019cites this paper
• The chemical biology of apoptosis: Revisited after 17 years.

  2019cites this paper
• c-FLIP, a Novel Biomarker for Cancer Prognosis, Immunosuppression, Alzheimer’s Disease, Chronic Obstructive Pulmonary Disease (COPD), and a Rationale Therapeutic Target

  2019cites this paper
• Selective Affimers Recognize BCL-2 Family Proteins Through Non-Canonical Structural Motifs

  2019cites this paper
• A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors

  2019cites this paper
• Rational Strategies for Combining Bcl-2 Inhibition with Targeted Drugs for Anti-Tumor Synergy

  2019cites this paper
• Importance of Hypericin-Bcl2 interactions for biological effects at subcellular levels.

  2019cites this paper
• Investigation of the molecular mechanism of paclitaxel-induced apoptosis in cultured-human cells

  2019cites this paper
• The potential role of tubeimosides in cancer prevention and treatment.

  2019cites this paper
• Transport and delivery of interferon-α through epithelial tight junctions via pH-responsive poly(methacrylic acid-grafted-ethylene glycol) nanoparticles

  2019cites this paper
• Resistance to drugs and cell death in cancer stem cells (CSCs)

  2019influential citation
• Staurosporine induces apoptosis in pancreatic carcinoma cells PaTu 8988t and Panc-1 via the intrinsic signaling pathway

  2019cites this paper
• Cancer Stem Cells, Apoptosis Pathways and Mechanisms of Death Resistance

  2019cites this paper
• Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution.

  2019cites this paper
• Curcumin and Melanoma: From Chemistry to Medicine

  2018cites this paper
• Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells

  2018cites this paper
• The cellular thermal shift assay : a novel strategy to study drug target engagement and resistance development in cancer therapy

  2018cites this paper
• Molecular dynamics investigations of structural and functional changes in Bcl-2 induced by the novel antagonist BDA-366

  2018cites this paper
• Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A.

  2018cites this paper
• Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma

  2017cites this paper
• The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells

  2017cites this paper
• Chondroitin sulfate-functionalized polyamidoamine as a tumor-targeted carrier for miR-34a delivery.

  2017cites this paper
• Readers of DNA methylation, the MBD family as potential therapeutic targets.

  2017cites this paper
• Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma

  2017cites this paper
• A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers

  2017cites this paper
• Apigenin in cancer therapy: anti-cancer effects and mechanisms of action

  2017cites this paper
• Caspase cleavage of Mcl-1 impairs its anti-apoptotic activity and proteasomal degradation in non-small lung cancer cells

  2017cites this paper
• Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain.

  2017cites this paper
• The anti-apoptotic protein MCL1, a novel target of lung cancer therapy

  2017cites this paper
• Search for Inhibitors of Ras-Driven Cancers

  2017cites this paper
• Dying: What Happens in the Cells and Tissues

  2017cites this paper
• Therapies Targeting Leukemic Stem Cells

  2017cites this paper
• An analysis of apoptotic and autophagic genes in novel Drosophila models of Parkinson disease

  2017cites this paper
• Expression of the uncharacterised isoform, BCL2β, in melanoma

  2017cites this paper
• The role of anti-apoptotic Bcl-2 proteins for colorectal cancer development and progression

  2017cites this paper
• Dying to protect: cell death and the control of T‐cell homeostasis

  2017cites this paper
• Therapeutic inhibition of BCL-2 and related family members

  2017cites this paper
• Promoting Vaginal Distribution of E7 and MCL-1 siRNA-Silencing Nanoparticles for Cervical Cancer Treatment.

  2017cites this paper
• Apoptotic effect of noscapine in breast cancer cell lines.

  2016cites this paper
• Are BH 3 Domain Peptides Appropriate Surrogates to Study BH 3-Only Protein Function ?

  2016cites this paper
• The Role of Inositol 1,4,5-Trisphosphate Receptor-Interacting Proteins in Regulating Inositol 1,4,5-Trisphosphate Receptor-Dependent Calcium Signals and Cell Survival

  2016influential citation
• New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia: Hypomethylating agents and proteasome inhibitors

  2016cites this paper
• Targeting cell death signalling in cancer: minimising ‘Collateral damage'

  2016cites this paper
• Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells

  2016cites this paper
• Mitochondria, cholesterol and cancer cell metabolism

  2016cites this paper
• Bcl-2 proteins bid and bax form a network to permeabilize the mitochondria at the onset of apoptosis

  2016influential citation
• Bcl-xL is an oncogenic driver in colorectal cancer

  2016cites this paper
• MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC.

  2016cites this paper
• Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas

  2016cites this paper
• BH3 mimetics: Their action and efficacy in cancer chemotherapy

  2016cites this paper
• Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line

  2016cites this paper
• Gossypol induces pyroptosis in mouse macrophages via a non-canonical inflammasome pathway.

  2016cites this paper
• Induction of Human Hepatocellular Carcinoma HepG2 Cell Apoptosis by Naringin.

  2016influential citation
• Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.

  2016cites this paper
• Resistance to Cell Death and Its Modulation in Cancer Stem Cells.

  2016cites this paper
• Physiological and Pharmacological Control of BAK, BAX, and Beyond.

  2016cites this paper
• Molecular Cell Biology of Apoptosis and Necroptosis in Cancer.

  2016cites this paper
• Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells

  2016cites this paper
• Development of a lytic peptide derived from BH3-only proteins

  2016cites this paper
• The Bcl-2 homologue Buffy rescues α-synuclein-induced Parkinson disease-like phenotypes in Drosophila

  2016cites this paper
• Voltage-Dependent Anion Channel 1(VDAC1) Participates the Apoptosis of the Mitochondrial Dysfunction in Desminopathy

  2016cites this paper
• Cdk2 phosphorylation of Bcl-xL after stress converts it to a pro-apoptotic protein mimicking Bax/Bak

  2016cites this paper
• Proteasome and HDAC Inhibition Changes the Expression Levels of Bcl-2, Bcl-XL, Bim and Bik Proteins in Androgen-Independent PC-3 Cell Line

  2015cites this paper
• Editorial overview: Cancer: Changing the landscape - new pharmacology steering the course towards improved treatment options in cancer.

  2015cites this paper
• Killing cancer with platycodin D through multiple mechanisms

  2015cites this paper
• Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling

  2015cites this paper
• Small‐Molecule and Peptide Inhibitors of the Pro‐Survival Protein Mcl‐1

  2015cites this paper